COO (The Cooper Companies, Inc.) — AI Stock Analysis & Recommendation

Research of September 22, 2026 · Healthcare / Ophthalmic Goods

TradeFlare's AI research teams rate COO a HOLD. The latest price is $54.59.

The research plan

• Entry: $55.29
• Target: $61.12
• Stop: $46.99
• Time horizon: weeks

The stock is in a downtrend with bearish technicals, and while fundamentals are strong, sentiment is negative, requiring a HOLD to observe further price action.

Why

The stock is in a downtrend with bearish technicals, and while fundamentals are strong, sentiment is negative, requiring a HOLD to observe further price action. Catalysts to watch: Strong underlying profitability and robust cash flow generation from The Cooper Companies; Undervalued forward P/E and PEG ratios suggesting potential for a rebound if market sentiment shifts; Analyst consensus 'buy' rating and target price indicating significant upside potential. Key risks: Strong bearish technical trend with price below key moving averages; Negative sentiment driven by activist investor pressure and recent analyst downgrades; High volatility and drawdown, coupled with potential for a short squeeze, indicating elevated risk.

What could push COO higher

• Strong underlying profitability and robust cash flow generation from The Cooper Companies.
• Undervalued forward P/E and PEG ratios suggesting potential for a rebound if market sentiment shifts.
• Analyst consensus 'buy' rating and target price indicating significant upside potential.

Key risks for COO

• Strong bearish technical trend with price below key moving averages.
• Negative sentiment driven by activist investor pressure and recent analyst downgrades.
• High volatility and drawdown, coupled with potential for a short squeeze, indicating elevated risk.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

The Cooper Companies (COO) presents a compelling bullish case driven by its undervalued status, indicated by a low forward P/E and PEG ratio, and strong analyst consensus. Its diversified healthcare business, robust profitability, and solid financial health, including significant free cash flow generation and manageable debt, provide a strong foundation for future growth and shareholder returns.

• The Cooper Companies (COO) exhibits strong profitability with a gross margin of 65.9% and a net margin of 13.5%, coupled with robust earnings growth (3.571%) significantly outpacing revenue growth (0.6%).
• The forward P/E ratio of 11.78 and a PEG ratio of 0.51 suggest the stock is undervalued relative to its expected earnings growth.
• Analyst consensus is overwhelmingly 'buy' with a mean target price of $66.21, indicating an upside potential of over 20% from the current price.

Technical team: Bearish

The overwhelming technical consensus points to a bearish outlook, driven by a strong downtrend, broken support, and bearish chart patterns. While some conflicting signals in volume and momentum suggest potential for short-term fluctuations, the overall trend and pattern analysis indicate a higher probability of further downside.

• The price is in a strong downtrend, trading below all key moving averages (MA20, MA50, MA200) and has recently broken below the $54.30 support level.
• While there was a recent volume spike suggesting potential accumulation near support, overall volume has been below average, indicating a lack of strong conviction in any direction.
• Momentum is mixed, with MACD showing bearish signals and RSI trending down, but Stochastic is indicating oversold conditions with a potential for a short-term bounce.

Sentiment team: Bearish

The Cooper Companies is experiencing deteriorating sentiment driven by significant headwinds, including activist investor pressure, recent analyst downgrades, and a failed strategic review. The stock's performance and the concerns raised by analysts and news coverage point towards a bearish outlook with limited immediate catalysts for improvement.

• News coverage for Cooper Companies (COO) is predominantly neutral, with a slight negative undertone driven by activist investor pressure for leadership changes and asset sales, alongside a recent failed auction of a key business unit which led to a stock...
• Cooper Companies (COO) exhibits neutral sentiment driven by a recent activist investor's call for leadership changes and asset sales, coupled with the company's decision to retain its CooperSurgical unit after a failed auction, while retail investor...
• The Cooper Companies faces significant headwinds, marked by recent analyst downgrades, activist investor pressure for leadership changes and asset sales, and a failed strategic review of a key business unit, leading to a predominantly negative sentiment....

Risk team: High

The stock presents a HIGH overall risk due to extreme volatility, a significant historical drawdown, and potential liquidity/short squeeze concerns, amplified by the binary nature of the biotech sector. Given these factors, a SMALL position size is recommended with a strict stop-loss to manage downside risk.

• High Volatility and Drawdown: The stock exhibits extremely high realized volatility across multiple timeframes (20d annualized at 60.2%, 10d HV at 77.5%) and has experienced a severe 1-year maximum drawdown of -52.11%, indicating substantial price swings...
• Liquidity Concerns and Short Squeeze Potential: The 'high_days_to_cover_gt_5' flag suggests a significant risk of short squeeze and potential for amplified price declines due to the time it would take for short sellers to cover their positions.
• Sector-Specific Binary Risk (Biotech/Pharma): Given the biotech/pharma sector context, the high volatility and drawdown are likely driven by binary, catalyst-dependent events such as clinical trial outcomes or regulatory decisions, introducing significant...

COO at a glance

Market value	$10.8B
Price / earnings	19.3
Revenue growth (year over year)	4.7%
Profit margin	13.5%
Debt / equity	0.23

Every AI call on COO since June 9, 2026, and what happened next (5 calls) →

Research of September 22, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.